Citations

Clear

3042 citation(s) found for "Kumar, S".

Acid-suppressive medications and risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: A systematic review and meta-analysis.
Singh, Siddharth , Garg, Sushil Kumar , Iyer, Prasad G. , El‐Serag, Hashem B. , Singh, Preet Paul

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 32 | Issue: 3_suppl | Pages: 11-11

10.1200/jco.2014.32.3_suppl.11 Get It

11 Background: Acid-suppressive medications, particularly proton pump inhibitors (PPI), may modify risk of esophageal adenocarcinoma (EAC) in patients with Barrett’s esophagus (BE). We performed a systematic review and meta-analysis of studies evaluating the association between PPIs and histamine receptor antagonists (H2RA) and risk of EAC or high-grade dysplasia (BE-HGD) in patients with BE. Methods: Through a systematic search up to June 2013, we identified 7 observational studies (5 cohort studies and 2 case-control studies; 2,813 patients with BE, 317 cases of EAC and/or BE-HGD, 84.4% PPI users) reporting the association between PPIs or H2RA and EAC in patients with BE. Summary odds ratio (OR) with 95% confidence intervals (CI) was estimated using random effects model, and heterogeneity was measured using the inconsistency index (I2). Results: On meta-analysis, PPI use was associated with 71% reduction in EAC risk in patients with BE (adjusted OR, 0.29; 95% CI, 0.12-0.71). There was a trend toward a dose-response relationship with PPI use for >2 years protective against EAC [3 studies; PPI use >2 years vs. <2 years (as compared to no use): OR, 0.45 (0.19-1.06) vs. 1.09 (0.47-2.56)]. Considerable heterogeneity was observed in the overall analysis (I2=81%). On restricting analysis to 5 cohort studies, use of PPIs was consistently associated with a lower risk of EAC and/or BE-HGD (adjusted OR, 0.33; 95% CI, 0.19-0.58; I2=9%). H2RA use was not associated with decreased risk of EAC in patients with BE based on 2 studies (adjusted OR, 1.15; 95% CI, 0.77-1.72). Using a 67% summary risk reduction (derived from cohort studies) of EAC and/or BE-HGD with PPI use in patients with BE, and observed cumulative incidence rates of EAC and/or BE-HGD in patients with BE overall as 10.2 per 1,000 patient years, we estimate the number needed to treat with PPIs to prevent 1 case of EAC or BE-HGD in BE patients at 147. Conclusions: Based on meta-analysis of observational studies, the use of PPI, but not H2RA appears to be associated with a decreased risk of EAC and/or BE-HGD in patients with BE. PPI use should be considered in BE, and chemopreventive trials of PPIs in patients with BE are warranted.
Improvement in survival of advanced hepatocellular carcinoma patients: Results of an updated period analysis of SEER database.
Shah, Binay Kumar , Bhandari, Amit , Ghimire, Krishna Bilas , Manandhar, Sajani

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 3_suppl | Pages: 383-383

10.1200/jco.2015.33.3_suppl.383 Get It

383 Background: Sorafenib was approved by FDA for treatment of advanced unresectable hepatocellular carcinoma (HCC) patients in November 2007. In this study, we update survival trends in advanced HCC using Surveillance, Epidemiology, and End Results (SEER) data. Methods: We selected patients with advanced HCC diagnosed from January 2001 to December 2010 from SEER 18 registries. We excluded diagnosed at autopsy, from death certificate only, or those without survival date. We calculated 1- and 2- year relative survival rates in pre-sorafenib (2001-2007) and post-sorafenib (2008-2010) era by age, sex and ethnicity among using SEER*stat software. Results: The total number of advanced HCC patients during 2001-2010, 2001-2007 and 2008-2010 were 5,092, 2,747 and 2,345 respectively. The 1- and 2- year survival rates of patients improved significantly from pre-sorafenib era to post-sorafenib era (1 year RS: 17.20±0.7% to 19.90±0.80%, Z=2.63; 2 year RS: 8.00±0.5% to 8.7±0.60%, Z=2.31). Survival rates of male patients improved significantly in post-sorafenib era (1 year RS: 16.4±0.80 to 19.4±0.90%, Z=2.18; 1 year RS: 7.4±0.60% to 8.6±0.70%, Z=2.18). There was no improvement in survival rates of female patients. Similarly, younger patients had improvement in survival rates in post-sorafenib era compared to pre-sorafenib era (1 year Z value 2.46; 2 year Z value 2.23). There was no improvement in survival rates of older patients. Conclusions: Since FDA approval of sorafenib, survival rates of patients with advanced hepatocellular carcinoma have improved. The improvement in survival rates is limited to males and younger patients
On Appetite and Its Loss
Jatoi, Aminah , Kumar, Shaji , Sloan, Jeff A. , Nguyen, Phuong

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 18 | Issue: 15 | Pages: 2930-2932

10.1200/jco.2000.18.15.2930 | PMID 10920143 Get It

Gene expression signatures of conventional prognostic factors in multiple myeloma
Haug, Janine , Shammas, Masood A. , Lacy, Martha Q. , Munshi, Nikhil C. , Kumar, Subodh , Rajkumar, S. Vincent , Li, Chaofan , Dispenzieri, Angela , Gertz, Morie A. , Witzig, Thomas E. , Anderson, Kenneth C.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6606-6606

10.1200/jco.2005.23.16_suppl.6606 Get It

A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR‐CD) for untreated low‐grade non‐Hodgkin lymphoma requiring therapy
Rosenthal, Allison , Dueck, Amylou C. , Ansell, Stephen M. , Gano, Katherine, Conley, Christopher J. , Nowakowski, Grzegorz S. , Camoriano, John , Leis, José F., Stewart, A. Keith , Inwards, David J. , Dingli, David , Kumar, Shaji , Noël, Pierre, Porrata, Luis F. , Russell, Stephen J. , Kapoor, Prashant , Tiedemann, Rodger E. , Reeder, Craig B. , Conley, Christopher , Mikhael, Joseph R., Inwards, David, Porrata, Luis, Russell, Stephen, Colgan, Joseph, Witzig, T.E. , Reeder, Craig, Dueck, A. C. , Rosenthal, Allison , Mıkhael, Joseph , Gertz, Morie A. , Colgan, Joseph P. , Fonseca, Rafaël , Habermann, Thomas M. , Buadi, Francis K. , Leung, Nelson , Witzig, Thomas E. , Russell, Stephen J , Dingli, David

Mayo Clinic

American Journal of Hematology | February 23, 2017 | Volume: 92 | Issue: 5 | Pages: 467-472

10.1002/ajh.24693 | PMID 28230270 Get It

AbstractPatients with indolent non‐Hodgkin lymphoma (NHL) have multiple treatment options yet there is no consensus as to the best initial therapy. Lenalidomide, an immunomodulatory agent, has single agent activity in relapsed lymphoma. This trial was conducted to assess feasibility, efficacy, and safety of adding lenalidomide to rituximab, cyclophosphamide, and dexamethasone (LR‐CD) in untreated indolent NHL patients requiring therapy. This was a single institution phase II trial. Treatment consisted of IV rituximab 375 mg/m2 day 1; oral lenalidomide 20 mg days 1–21; cyclophosphamide 250 mg/m2 days 1, 8, and 15; and dexamethasone 40 mg days 1, 8, 15, and 22 of a 28‐day cycle. Treatment continued 2 cycles beyond best response for a maximum of 12 cycles without rituximab maintenance. Thirty‐three patients were treated. Median age was 68 (43–83 years). 39% had stage IV disease. Histologic subtypes included 8 follicular lymphoma (FL), 7 marginal zone lymphoma (MZL) (1 splenic, 2 extranodal, and 4 nodal), 15 Waldenström's macroglobulinemia (WM), 1 lymphoplasmacytic lymphoma, 1 small lymphocytic lymphoma, and 1 low‐grade B‐cell lymphoma with plasmacytic differentiation (unable to be classified better as MZL or LPL). Hematologic toxicity was the most common adverse event. Median time of follow‐up was 23.4 months (range 1.8–50.9). The overall response rate was 87.9%, with 30.3% complete response. The median duration of response was 38.7 months. The median progression free survival was 39.7 months, while median overall survival (OS) has not yet been reached. Lenalidomide can be safely added to a simple regimen of rituximab, oral cyclophosphamide, and dexamethasone and is an effective combination as initial therapy for low‐grade B‐cell NHL.
Prophylactic Plasma Transfusion Is Not Associated With Decreased Red Blood Cell Requirements in Critically Ill Patients
Warner, Matthew A. , Jenkins, Gregory D. , Kor, Daryl J. , Chandran, Arun Kumar , Warner, Matthew A

Mayo Clinic

Anesthesia & Analgesia | February 11, 2017 | Volume: 124 | Issue: 5 | Pages: 1636-1643

10.1213/ane.0000000000001730 | PMID 28181937 Get It

BACKGROUND: Critically ill patients frequently receive plasma transfusion under the assumptions that abnormal coagulation test results confer increased risk of bleeding and that plasma transfusion will decrease this risk. However, the effect of prophylactic plasma transfusion remains poorly understood. The objective of this study was to determine the relationship between prophylactic plasma transfusion and bleeding complications in critically ill patients. METHODS: This is a retrospective cohort study of adults admitted to the intensive care unit (ICU) at a single academic institution between January 1, 2009 and December 31, 2013. Inclusion criteria included age ≥18 years and an international normalized ratio measured during ICU admission. Multivariable propensity-matched analyses were used to evaluate associations between prophylactic plasma transfusion and outcomes of interest with a primary outcome of red blood cell transfusion in the ensuing 24 hours and secondary outcomes of hospital- and ICU-free days and mortality within 30 days of ICU discharge. RESULTS: A total of 27,561 patients were included in the investigation with 2472 (9.0%) receiving plasma therapy and 1105 (44.7%) for which plasma transfusion was prophylactic in nature. In multivariable propensity-matched analyses, patients receiving plasma had higher rates of red blood cell transfusion (odds ratio: 4.3 [95% confidence interval: 3.3–5.7], P < .001) and fewer hospital-free days (estimated % increase: −11.0% [95% confidence interval: −11.4, −10.6%], P < .001). There were no significant differences in ICU-free days or mortality. These findings appeared robust, persisting in multiple predefined sensitivity analyses. CONCLUSIONS: Prophylactic administration of plasma in the critically ill was not associated with improved clinical outcomes. Further investigation examining the utility of plasma transfusion in this population is warranted.
Hematology patient reported symptom screen to assess quality of life for AL amyloidosis
Warsame, Rahma , Kumar, Shaji , Lacy, Martha Q. , Hayman, Suzanne R. , Dingli, David , Lust, John A., Lin, Yi , Russell, Stephen J. , Kapoor, Prashant , Kourelis, Taxiarchis , Zeldenrust, Steven R., Kyle, Robert A. , Sloan, Jeffrey A., Buadi, Francis K. , Russell, Stephen, Go, Ronald S , Sloan, Jeffrey, Gertz, Morie A. , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Zemla, Tyler , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi

Mayo Clinic

American Journal of Hematology | February 9, 2017 | Volume: 92 | Issue: 5 | Pages: 435-440

10.1002/ajh.24676 | PMID 28181278 Get It

AbstractPatients with light chain amyloidosis (AL) often have delayed diagnosis and present with significant symptomatology; this may result in decreased quality of life (QOL). We prospectively employ a “Hematology Patient Reported Symptom Screen” (HPRSS), which is three questions about fatigue, pain, and QOL, scored 0–10. The aim of this study is to better understand QOL and determine if HPRSS parameters predict for clinical outcomes. From 2009 to 2014, 302 newly diagnosed AL patients were included. Baseline median scores [interquartile range] for fatigue, pain, and QOL were 6 [3,7], 2 [0,5], 5 [3,8], respectively. Median overall survival was 53 months, with 102 (34%) deaths in the first year. There were significant differences in baseline HPRSS between those that lived longer than one year and early death patients in the domains of fatigue (5 [IQR 3, 7] vs. 7 [IQR 5, 8], P < 0.0001) and QOL (6 [IQR 4, 8] vs. 5 [IQR 3, 7], P = 0.006). On univariate analysis fatigue, QOL, physician‐reported performance status, autologous stem cell transplant (ASCT), and Mayo stage were prognostic for survival. On multivariate analysis Mayo stage, ASCT, and baseline fatigue remained independently prognostic. When analyses were restricted to the 125 patients with HPRSS measurements at 12 months, we found that over time QOL scores improved significantly 6 [IQR 3.5, 8] → 7 [IQR 5, 8] (P = 0.01). Asking AL patients to rate their fatigue and QOL has predictive value. Baseline patient reported fatigue is an independent prognostic factor for survival. Survival at one year was associated with significant improvement in QOL.
Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta‐regression analysis
Mainou, Maria , Madenidou, Anastasia‐Vasiliki , Liakos, Aris , Paschos, Paschalis , Karagiannis, Thomas , Bekiari, Eleni , Vlachaki, Efthymia , Murad, M. Hassan , Kumar, Shaji , Τσάπας, Απόστολος , Murad, Mohammad Hassan, Wang, Zhen , Liakos, A , Tsapas, A , Murad, M Hassan , Karagiannis, Thomas , Bekiari, Eleni

Mayo Clinic

European Journal of Haematology | February 8, 2017 | Volume: 98 | Issue: 6 | Pages: 563-568

10.1111/ejh.12868 | PMID 28178364 Get It

AbstractObjectivesWe performed a systematic review and meta‐regression analysis of randomized control trials to investigate the association between response to initial treatment and survival outcomes in patients with newly diagnosed multiple myeloma (MM).MethodsResponse outcomes included complete response (CR) and the combined outcome of CR or very good partial response (VGPR), while survival outcomes were overall survival (OS) and progression‐free survival (PFS). We used random‐effect meta‐regression models and conducted sensitivity analyses based on definition of CR and study quality.ResultsSeventy‐two trials were included in the systematic review, 63 of which contributed data in meta‐regression analyses. There was no association between OS and CR in patients without autologous stem cell transplant (ASCT) (regression coefficient: .02, 95% confidence interval [CI] −0.06, 0.10), in patients undergoing ASCT (−.11, 95% CI −0.44, 0.22) and in trials comparing ASCT with non‐ASCT patients (.04, 95% CI −0.29, 0.38). Similarly, OS did not correlate with the combined metric of CR or VGPR, and no association was evident between response outcomes and PFS. Sensitivity analyses yielded similar results.ConclusionsThis meta‐regression analysis suggests that there is no association between conventional response outcomes and survival in patients with newly diagnosed MM.
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
Muchtar, Eli , Gertz, Morie A. , Kumar, Shaji , Lacy, Martha Q. , Dingli, David , Grogan, Martha , Hayman, Suzanne R. , Kapoor, Prashant , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Warsame, Rahma , Kourelis, Taxiarchis , Russell, Stephen J. , Lust, John A., Lin, Yi , Zeldenrust, Steven R., Kyle, Robert A. , Buadi, Francis K. , Leung, Nelson , Gonsalves, Wilson I. , Go, Ronald S. , Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A , Muchtar, E , Russell, Stephen J , Dingli, David , Lin, Yi

Mayo Clinic

Blood | January 26, 2017 | Volume: 129 | Issue: 15 | Pages: 2111-2119

10.1182/blood-2016-11-751628 | PMID 28126928 Get It

Key Points Significant improvement in outcome is a reality for newly diagnosed AL amyloidosis in the past decade. Six-month mortality among transplant ineligible patients has declined since 2005.